Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Clinical Impact of Chronic Low-Grade Nausea Is Woefully Underestimated

Maurie Markman, MD
Published: Wednesday, Nov 01, 2017
Maurie Markman, MD

Maurie Markman, MD
Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era. Examples include cyclophosphamide in breast cancer and melphalan in ovarian cancer. More recent experiences include an expanded use of oral hormonal therapy in several malignancies and a number of molecularly targeted therapeutics in routine clinical practice.

Conversely, nausea described in clinical trial analyses and subsequent peer-reviewed publications as being “low-grade” (grade 1) would likely be considered as having a limited or minimal impact on a patient’s overall quality of life and might even be classified as being “acceptable.”

Impact on Adherence

Now, fast forward to the current era where the paradigm is rapidly shifting to include highly clinically active orally administered antineoplastic drugs, where such therapy is routinely delivered daily or several times a day and where treatment may be continued for many years, either for a known active cancer or in a maintenance setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication